LCT and infection: DIBI inhibited clinical A. baumanii isolates at MICs below those of typical antibiotics; low-dose nasal administration of DIBI after intranasal challenge with ciprofloxacin-resistant A. baumanii LAC-4 significantly reduced the bacterial burden in mice and DIBI also inhibited the spread of infection to the spleen. Given the ciprofloxacin resistance of LAC-4, treatment of infected mice with ciprofloxacin alone was ineffective, but treatment with DIBI greatly enhanced the therapeutic effect.